Promises
1 promise
Promise Tracker
1 delivered, 0 close, 0 missed.
View Promises →
Ajanta Pharma Limited — Q3 FY24
Ajanta Pharma reported a strong Q3 FY24 with consolidated revenue of INR 1,105 crore, up 14% YoY, driven by broad-based growth across branded generics.
bullish
high
Financial stats pending filing verification
2-Minute Summary
✦ AI-Generated from Full Transcript
Ajanta Pharma reported a strong Q3 FY24 with consolidated revenue of INR 1,105 crore, up 14% YoY, driven by broad-based growth across branded generics. EBITDA margin held steady at 28%, supported by improved gross margins and lower logistics costs. PAT surged to INR 210 crore from INR 135 crore a year ago. The India business grew 5% (9M: 11%), outpacing IPM by 200 bps, while Asia branded grew 28% (aided by spillover) and Africa institutional jumped 179%. US generics declined 5% due to a high base from last year's flu season. Management guided for FY24 EBITDA margin of 27% ±1%, factoring in Red Sea freight headwinds and higher Q4 expenses. Key risks include US price erosion and unpredictable institutional business. Overall, the company is well-positioned with a strong balance sheet, consistent cash generation, and a disciplined capital allocation policy.
अजंता फार्मा ने तीसरी तिमाही में अच्छा प्रदर्शन किया। कंपनी की कुल कमाई 1,105 करोड़ रुपये रही, जो पिछले साल से 14% ज्यादा है। यह बढ़ोतरी दवाओं की बिक्री बढ़ने से हुई। कंपनी का मुनाफा 210 करोड़ रुपये हो गया, जो पिछले साल 135 करोड़ रुपये था। भारत में कारोबार 5% बढ़ा, एशिया में 28% और अफ्रीका में 179% का उछाल आया। अमेरिका में बिक्री 5% घटी क्योंकि पिछले साल फ्लू के कारण ज्यादा बिक्री हुई थी। कंपनी को लगता है कि इस साल मुनाफा 27% के आसपास रहेगा। समुद्री रास्ते में परेशानी और साल के अंत में ज्यादा खर्च से सावधानी बरतनी होगी। कुल मिलाकर कंपनी मजबूत स्थिति में है।
Promises1 met · 0 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Risks
4 risks
Risk Intelligence
Red Sea crisis impacting freight costs and transit times
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
India Business Growth (9M)
11%
+11% YoY
India business grew 11% in 9M FY24, outpacing IPM growth of 10%.
Asia Branded Growth (Q3)
28%
+28% YoY
Asia branded sales grew 28% in Q3, partly due to spillover from Q2.
US Generics Growth (9M)
11%
+11% YoY
US generics grew 11% in 9M, with price erosion stabilizing at high single digits.
Africa Institutional Growth (Q3)
179%
+179% YoY
Africa institutional sales surged 179% in Q3 due to order postponement from Q4.
What Changed vs Last Quarter
NEW
India business to grow low double digits in FY24
India business expected to grow 12-13% for full year FY24, with Q4 aspiration to cross 15%.
NEW
Asia branded to grow low teens in FY24
Asia branded business expected to grow low double digits for full year FY24.
NEW
Africa branded to grow mid to high single digits in FY24
Africa branded business expected to grow mid to high single digits for full year FY24.
UPDATED
FY24 EBITDA margin guidance revised to 27% ±1%
Management revised full-year EBITDA margin guidance to 27% ±1%, down from 28% in 9M, due to higher freight costs from Red Sea crisis and increased Q4 expenses.
DROPPED
Asia branded business to deliver low-teens growth in FY24
Despite an 8% decline in Q2, management expects Asia branded business to post low-teens growth for the full year, driven by recovery in H2.
DROPPED
Africa branded business to deliver low-teens growth in FY24
Africa branded business is expected to bounce back and deliver low-teens growth for FY24, after a flattish H1.
DROPPED
US revenues to sustain at similar levels for next two quarters
Management expects US generics revenue to remain at Q2 levels for the next two quarters, factoring in new launches and market share changes.
NEW RISK
Red Sea crisis impacting freight costs and transit times
Freight costs may increase by ~0.5% of revenue (~INR 30-35 crore) and transit times by 15-20 days, potentially pressuring margins and working capital.
NEW RISK
Unpredictability of Africa institutional business
Institutional business is lumpy and dependent on agency funding and malaria season, making it difficult to forecast.
NEW RISK
NLEM price revisions impacting India cardiology growth
Cardiology growth was lower than IPM due to price revision in a major product in December 2022, and competitive intensity has increased.
RISK GONE
Asia branded business decline due to shipment push-outs
Asia branded sales declined 8% YoY in Q2 due to supplies pushed to next quarter; recovery depends on execution.
RISK GONE
Africa market slowdown may persist
Africa branded business saw a slowdown in the market over the last 4-5 months; growth recovery is uncertain.
RISK GONE
Chantix launch timing uncertain
Chantix launch is delayed to Q4 FY24 or Q1 FY25; any further delay could impact US revenue expectations.
🤫 Topics management stopped discussing
Mentioned in Q1 FY24, Q2 FY24
Chantix launch is delayed to Q4 FY24 or Q1 FY25; any further delay could impact US revenue expectations.
Fast read
Guidance and risk preview
Management revised full-year EBITDA margin guidance to 27% ±1%, down from 28% in 9M, due to higher freight costs from Red Sea crisis and increased...
Freight costs may increase by ~0.5% of revenue (~INR 30-35 crore) and transit times by 15-20 days, potentially pressuring margins and working capital.
View Risks →